August 3, 2020
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB
July 22, 2020
Global Health Leaders Chart the Path Forward in Pandemic Response
Dr. Anthony Fauci Calls for a Unified Approach and Continuous Commitment to Pandemic Preparedness
July 22, 2020
Mylan Secures DCGI Approval in India for Pretomanid, a Treatment for Highly Drug-Resistant Forms of Tuberculosis
June 18, 2020
New Report Highlights Urgent Need for Improved Treatments for Children with MDR-TB
Tuberculosis is a leading cause of death worldwide. Children with drug-resistant TB need improved treatment options
June 5, 2020
Standing Against Racism and Injustice
A Message to the TB Alliance Family
June 2, 2020
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
TB Alliance to leverage AlphaMeld, an AI-powered platform to capture and accelerate innovation to address unmet needs
May 28, 2020
TB Alliance Commercialization Partner, Mylan, Launches Named Patient Access Program for New Highly Resistant TB Treatment
The NPAP is designed for patients in countries where regulatory approval or other access mechanisms are not yet available
April 21, 2020
A Conversation with Mitchell Warren
How the TB Alliance Stakeholders Association Will Help Realize the Promise of New Therapies
March 24, 2020